解毒劑
1. Drug action reversal of Dabigatran
2. Life-threatening or uncontrolled bleeding or when emergency surgery or procedures are required

Monoclonal Antibody Antidote
Idarucizumab neutralizes the anticoagulant effect of dabigatran by binding to dabigatran and its acylglucuronide metabolites. The binding affinity for idarucizumab is higher than that of dabigatran to thrombin.

Distribution
Vd: 8.9 L
Excretion
Renal: 32.1% to 38.9% unchanged
Elimination Half Life
8.11 to 10.3 hours

Specific contraindications have not been determined

Fetal risk cannot be ruled out. (TH)

Infant risk cannot be ruled out.(MDX)

Common
Endocrine metabolic: Hypokalemia
Gastrointestinal: Constipation
Psychiatric: Delirium
Respiratory: Pneumonia
Other: Fever
Serious
Hematologic: Coag./bleeding tests abnormal, Thromboembolic disorder
Immunologic: Hypersensitivity reaction

IV 5 g (administered as 2 separate 2.5 g doses no more than 15 minutes apart); limited data support the use of an additional 5 g if coagulation parameters re-elevate in the presence of clinically relevant bleeding, or if another emergency procedure is needed.
-
Dabigatran can be reinitiated 24 hours after administration

Safety and efficacy not established in pediatric patients.

No adjustment required.